events were tracked through Medicare claims, and medical care costs were assessed from the Medicare payment perspective. Clinical restenosis was defined as the occurrence of any repeat revascularization between 1 and 12 months after initial PCI.
Results: Within this elderly PCI population (n=l0,308, mean age 73.9 yrs), 36.6% were diabetic. Crude restenosis rates ware significantly higher for diabetics (11.9% vs. 8.4%, p<O.OOl) and remained 32% higher in adjusted analyses (see Table) . Restenosis increased follow-up medical care costs by $20,745 for DM patients and by $18,365 for non-DM patients (pcO.001 for DM vs. non-DM). The attributable l-year costs of restenosis were $2,469 and $1,543 per patient, for DM and non-DM patients respectively.
Conclusions:
Among unselected, elderly patients undergoing PCI, DM is associated with m an increased risk of restenosis and higher costs for treatment of restenosis.
These findings have important implications for the cost-effectiveness of drug-eluting stents in both DM and non-DM populations. In the UK. most hioh-risk Datients with non-ST elevation acute coronaw svndromes (ACS) are managed without direct access to coronary interventions, leading'to uncertaintv about the cost imDact of GP Ilblllla inhibitors in this relativelv low interventional setting. We estimated the cost par event avoided &PEA) of tirofiban in this setting.
Methods:
Data from a UK registry (PRAIS-UK. n=l046) for high-risk ACS pts (TIMI 23) were used in a decision model with hierarchical outwme rates of death, non-fatal MI, and rehospitalization for ACS, with pts managed invasively or non-invasively, with or without tirofiban (cost f584 for 4 vials), applying local costs of care. Risk reductions were used March 19,2003 from the PRISM-PLUS trial and adjusted for invasive management strategies with results of the TACTICS trial. Regression models were fitted for cost estimation with outcomes, treatment arms and interactions between them. Sensitivity analyses were performed on %'of pts managed invasively, main cost drivers (e.g. tirofiban, PTCA) and baseline outcome rates.
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Limitations:
In the absence of a relevant single trial, data from 2 trials were used to derive probabilities accepting inevitable differences between trials such as practice patterns.
Results: See Two different cost-effectiveness approaches were used: In one method the median time gain of prehospital fibrinolysis, compared with in-hospital fibrmolysis, was matched with the associated risk reduction calculated on the basis of the literature. Costs of prehospital diagnosis and treatment were added to the suwival after 30 days, and cost effectiveness was estimated as the additional costs due to prehospital fibrinolysis divided by the number of life years gained. In the other method a mathematical model was used to simulate patient histories, each drawn from a certain risk profile, whereby two histories were simulated for each patient. one with prehospital, and one with in-hospital treatment.
Results
In the first model, with a risk reduction of 30% for in-hospital, and 35% for prehospital treatment, prehospital fibrinolysis resulted I" costs per life year gained at EUR 2,600. Using the second model, with simulation of patient histories and according risk profiles, the average 30.day survival with prehospital fibrinolysls was 93.73% compared to 93.32% with in-hospital fibrinolysis. Assuming an average life expectancy of 10 years after discharge, this results in an estimated cost per life year gained of EUR 1,837.
Conclusion:
Prehospital fibrinolysis costs EUR t ,800 to 2,800 per life year gained and seems, therefore, at least as cost-effective as other evidence-based infarct treatments. Study (APRES) found ramipril, in addition to usual care, was associated with lower mortality and a trend towards fewer non-fatal cardiac events in patients after PCI. Methods: A decision analytic model was developed to evaluate the cost-effectiveness of ramipril, using only direct medical costs. Efficacy data on cardiac mortality, non-fatal events such as acute myocardial infarction, congestive heart failure, and angina pectoris associated with ramipril (n=80) or placebo (n=79) were obtained from APRES. Effectiveness was defined, in terms of life years gained (LYG) using the persistent benefit approach, as the product of within-trial cardiac mortality and projected remaining life of 11.6 years. Risk reduction in non-fatal events were included to model expected cost reductions. Serwtivity analyses were conducted on a range of unit costs, event rates and survival duration. Unit costs were derived from national databases (HCUP-III and Medicare) and published literature. Drug costs were based on the Red Book and all costs were discounted at 3% !xr war. .
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Routine Use of Ramipril Is Cost-Effective After Percutaneous Coronary Intervention
Results: After accounting for cost offsets due to reduced coronary events, the total exmxted incremental costs were 51.896 for ramkxil and 51.434 for olacebo. vieldina a _ _ net incremental cost of therapy of $462 per patient discounted over 33 months. Cost of therapy translated to $6,079 per death averted, and an incremental cost-effectiveness ratio (ICER) of $524 per LYG. The within-trial survival ICER was 2,21O/LYG. In sensitivity analyses, the ICER vaned from $G/LYG to $l.O39/LYG using the best and worst case scenarios. Global sensitivity showed that the ICER ranged from a net cost saving to $l8,982/LYG under the best and worst scenarios.
Conclusions:
The ICER for ramipril is well within the societal willingness-to-pay for an additional LYG, even under the worst case scenarios. Routine use of ramipril is costeffective in improving suwival after PCI in patients with chrorw stable angina.
